



CONFIDENTIAL

Subject: Notification Pursuant to 18 V.S.A. § 4637

April 5, 2024

To the Office of the Vermont Attorney General:

Pursuant to 18 V.S.A. § 4637(b), Chartwell RX, LLC (Chartwell) hereby notifies the Office of the Vermont Attorney General that Chartwell has introduced a new generic prescription drug at a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program. of the commercial release of the following prescription drug:

Name of Prescription Drug	NDC Number	Date of Commercial Availability	WAC per Bottle	WAC per 30-day course of therapy
Imatinib Mesylate Oral Tablet 100 MG	62135-0658-90	Mar. 25, 2024	\$900.00	\$1,200.00

Marketing and Pricing Plans Used at Launch	Estimated Volume of Patients	Breakthrough Therapy Designation / Priority Review	Date and Price of Acquisition (if applicable)
Pursuant to 18 V.S.A. § 4637(d), Chartwell is limiting its response to that which is otherwise in the public domain or publicly available. Chartwell's marketing and pricing plans for this drug product are neither in the public domain nor publicly available.	The estimated volume of patients per month is unknown to Chartwell and unavailable through publicly available resources. Accordingly, Chartwell is limiting its response to this item pursuant to 18 V.S.A. § 4637(d).	N/A	Pursuant to 18 V.S.A. § 4637(d), Chartwell is limiting its response to that which is otherwise in the public domain or publicly available.

Sincerely,

Jack Goldenberg
Managing Member